Market Valuation & Earnings Multiples
Market capitalization, P/E ratios, and enterprise value
Market Cap374.21M
Enterprise Value324.20M
Trailing P/E22.22
Forward P/E10.98
NAGE
(NASDAQ)Niagen Bioscience, Inc.
$4.38-- (--)
Loading... - Market loading
Niagen Bioscience (NAGE) Key Statistics & Financial Metrics
Complete stock analysis with 40+ metrics: valuation ratios, profitability margins, financial health indicators, and dividend data.
Stock Valuation Metrics
Market value, earnings multiples, and pricing ratios
Price-Based Ratios
Valuation ratios based on stock price
Price/Sales (ttm)2.98
Forward Price/Sales2.30
Price/Book (mrq)5.05
Price/Tangible Book (mrq)5.45
Price/FCF (ttm)29.35
Price/OCF (ttm)28.71
PEG Ratio0.22
Enterprise Value Ratios
EV-based valuation multiples
EV/Revenue2.50
EV/Earnings18.65
EV/EBITDA19.96
EV/EBIT16.79
EV/FCF24.64
Stock Price
Current price, 52-week range, and moving averages
Current Price$4.38
1-Day Change2.49%
52-Week High$14.69
52-Week Low$4.16
52-Week Change-34.21%
YTD Change-27.68%
1-Year Change-36.16%
50-Day MA$5.14
200-Day MA$7.82
Avg Volume (30 day)750.88K
Share Statistics
Outstanding shares, float, and per-share metrics
Shares Outstanding85.44M
Book Value per Share$0.90
Net Cash per Share$0.75
FCF per Share$0.15
Analyst Price Targets & Consensus
Wall Street analyst ratings and 12-month price targets (90 days)
Price Target$13.00
Target Upside/Downside196.80%
Analyst ConsensusBuy
Analyst Count1
Profitability & Financial Performance
Profit margins, return metrics, and earnings analysis
Profit Margins
Profitability margins across income statement
Gross Margin64.28%
EBITDA Margin (ttm)12.55%
EBIT Margin (ttm)14.92%
Operating Margin (ttm)11.05%
Pretax Margin (ttm)14.06%
Profit Margin (ttm)13.43%
FCF Margin (ttm)10.17%
Return on Investment Metrics
ROE, ROA, ROIC, and capital efficiency ratios
Return on Equity (ttm)22.71%
Return on Assets (ttm)16.34%
Return on Invested Capital (ttm)126.66%
Return on Capital Employed (ttm)22.32%
Income Statement (TTM)
Trailing twelve months revenue and earnings
Revenue129.42M
Gross Profit83.19M
Operating Income14.30M
Pretax Income18.19M
Net Income17.38M
EBITDA16.24M
EBIT19.30M
Diluted EPS$0.21
Cash Flow (TTM)
Operating cash flow and free cash flow metrics
Operating Cash Flow13.45M
Capital Expenditures292.00K
Free Cash Flow13.16M
Growth Rates (YoY)
Year-over-year growth metrics
Revenue Growth29.95%
Financial Health & Dividends
Balance sheet analysis, debt ratios, and dividend metrics
Assets & Cash
Total assets and cash positions
Total Assets (mrq)106.41M
Cash & Securities (mrq)64.79M
Net Cash (mrq)63.79M
Net Cash per Share$0.75
Debt & Liabilities
Liabilities, debt, equity, and working capital
Total Debt (mrq)2.82M
Working Capital (mrq)76.89M
Total Equity (mrq)76.53M
Book Value per Share$0.90
Liquidity & Leverage
Liquidity, leverage, and debt coverage ratios
Current Ratio (mrq)4.86
Quick Ratio (mrq)3.83
Debt/Equity (mrq)0.04
Debt/EBITDA (ttm)0.17
Debt/FCF (ttm)0.21
Dividend History & Payout Analysis
Dividend yield, payout ratios, and growth metrics
Dividend per Share (TTM)$0.00
Dividend Yield0.00%
Payout Ratio (Earnings)0.00%
Yield Metrics
Earnings, FCF, buyback, and shareholder yields
Earnings Yield4.50%
FCF Yield3.41%
Buyback Yield0.06%
Total Shareholder Yield0.06%
Financial Health Scores
Risk assessment and quality metrics
Altman Z-Score8.27
Piotroski F-Score5/9
Fair Value & Intrinsic Value
Lynch fair value, Graham number, and valuation models
Lynch Fair Value$20.79
Lynch Upside/Downside359.86%
Graham Number$2.04
Graham Upside/Downside-54.94%
Frequently Asked Questions About Niagen Bioscience Statistics
What are the key financial metrics for NAGE?
Niagen Bioscience, Inc. (NAGE) statistics include 40+ financial metrics organized into valuation ratios (P/E, P/S, P/B, PEG), profitability margins (gross, operating, net), return metrics (ROE, ROA, ROIC), and financial health indicators. These are updated regularly based on the latest filings and market data.
What is NAGE's valuation analysis?
The valuation section covers market capitalization, earnings multiples like trailing and forward P/E, price-based ratios (P/S, P/B, Price/FCF), and enterprise value ratios (EV/EBITDA, EV/Revenue, EV/FCF). Compare these against sector averages to assess whether Niagen Bioscience is overvalued or undervalued.
How do I read NAGE's profitability ratios?
Niagen Bioscience's profitability is measured through profit margins (gross, EBITDA, operating, net) and return metrics (ROE, ROA, ROIC, ROCE). Higher margins indicate better cost control, while higher returns show efficient capital deployment. The income statement and cash flow sections provide the underlying revenue and earnings data.
What do NAGE's debt ratios indicate?
The financial health section shows Niagen Bioscience's leverage through debt-to-equity, debt-to-assets, debt-to-EBITDA, and debt-to-FCF ratios, plus liquidity via the current and quick ratios. Lower debt ratios and higher liquidity ratios generally indicate stronger financial stability and lower default risk.
What is NAGE's dividend analysis?
The dividend section covers Niagen Bioscience's dividend yield, payout ratios (earnings-based and FCF-based), year-over-year dividend growth, years of consecutive growth, ex-dividend and pay dates, and payment frequency. The yield metrics section also includes earnings yield, FCF yield, buyback yield, and total shareholder yield.